Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Cureus ; 15(6): e40099, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37425552

ABSTRACT

BACKGROUND: Non-melanoma skin cancer (NMSC) is the most common human malignancy worldwide, with increasing incidence in the United States (US). Recent environmental data have shown that ultraviolet radiation (UVR) levels have increased in the US, particularly in the higher latitudes, but the potential impact of this on NMSC incidence is not well known, despite estimates that 90% of NMSC is due to sun exposure. Our exploratory study synthesizes environmental data with demographic and clinical data to determine whether UV indices (UVIs) and non-sunbelt (non-SB) locale (latitudes >40 degrees, which comprises most of the US) might contribute to incidence rates of two types of NMSC: cutaneous squamous cell and Merkel cell carcinomas. METHODS: UVIs from 2010 to 2017 were obtained from the National Oceanic and Atmospheric Administration database and meshed with corresponding locales in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database (version 8.4.0.1). Four SB and five NSB locales contained sufficient data for analysis. Linear mixed modeling was performed with the outcome variable of the age-adjusted incidence of NMSC cancer (comprised of cutaneous squamous cell carcinoma of the head and neck (CSCCHN) and Merkel cell carcinoma (MCC)), the two most common types of NMSC contained within SEER). Non-SB locale and percent of days with UVI >3 were independent variables. RESULTS: Percent of days with UVI >3 increased during this period, as did the overall NMSC (combined CSCCHN and MCC) skin cancer incidence, though MCC incidence alone did not increase during our study period. Environmental factors that significantly contributed to the age-adjusted overall NMSC (combined CSCCHN and MCC) cancer incidence (per 100,000 individuals) included NSB locale (b=1.227, p=0.0019) and percent of days with UVIs >3 (b=0.028, p<0.0001), as well as clinical factors of percent white race and percent male, by linear mixed modeling. CONCLUSIONS: Our results are limited by the completeness of the NOAA and SEER databases, and do not include basal cell carcinoma. Nevertheless, our data demonstrate that environmental factors, such as latitude in NSB locale and UVI indices, can affect the age-adjusted overall NMSC (defined as CSCCHN and MCC in this study) incidence even in this relatively short period of time. Prospective studies over longer time periods are needed to identify the extent to which these findings are clinically significant so that increased educational efforts to promote sun-safe behaviors can be maximally effective.

2.
PLoS One ; 18(7): e0289171, 2023.
Article in English | MEDLINE | ID: mdl-37498822

ABSTRACT

Reproducibility is crucial for scientific progress, yet a clear research data analysis workflow is challenging to implement and maintain. As a result, a record of computational steps performed on the data to arrive at the key research findings is often missing. We developed Scikick, a tool that eases the configuration, execution, and presentation of scientific computational analyses. Scikick allows for workflow configurations with notebooks as the units of execution, defines a standard structure for the project, automatically tracks the defined interdependencies between the data analysis steps, and implements methods to compile all research results into a cohesive final report. Utilities provided by Scikick help turn the complicated management of transparent data analysis workflows into a standardized and feasible practice. Scikick version 0.2.1 code and documentation is available as supplementary material. The Scikick software is available on GitHub (https://github.com/matthewcarlucci/scikick) and is distributed with PyPi (https://pypi.org/project/scikick/) under a GPL-3 license.


Subject(s)
Computational Biology , Software , Computational Biology/methods , Workflow , Reproducibility of Results , Data Analysis
5.
Bioinformatics ; 2019 Nov 08.
Article in English | MEDLINE | ID: mdl-31702788

ABSTRACT

MOTIVATION: Biological rhythmicity is fundamental to almost all organisms on Earth and plays a key role in health and disease. Identification of oscillating signals could lead to novel biological insights, yet its investigation is impeded by the extensive computational and statistical knowledge required to perform such analysis. RESULTS: To address this issue, we present DiscoRhythm (Discovering Rhythmicity), a user-friendly application for characterizing rhythmicity in temporal biological data. DiscoRhythm is available as a web application or an R/Bioconductor package for estimating phase, amplitude, and statistical significance using four popular approaches to rhythm detection (Cosinor, JTK Cycle, ARSER, and Lomb-Scargle). We optimized these algorithms for speed, improving their execution times up to 30-fold to enable rapid analysis of -omic-scale datasets in real-time. Informative visualizations, interactive modules for quality control, dimensionality reduction, periodicity profiling, and incorporation of experimental replicates make DiscoRhythm a thorough toolkit for analyzing rhythmicity. AVAILABILITY AND IMPLEMENTATION: The DiscoRhythm R package is available on Bioconductor (https://bioconductor.org/packages/DiscoRhythm), with source code available on GitHub (https://github.com/matthewcarlucci/DiscoRhythm) under a GPL-3 license. The web application is securely deployed over HTTPS (https://disco.camh.ca) and is freely available for use worldwide. Local instances of the DiscoRhythm web application can be created using the R package or by deploying the publicly available Docker container (https://hub.docker.com/r/mcarlucci/discorhythm). SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

6.
Nat Commun ; 10(1): 2246, 2019 05 21.
Article in English | MEDLINE | ID: mdl-31113950

ABSTRACT

Epigenetic control of enhancers alters neuronal functions and may be involved in Alzheimer's disease (AD). Here, we identify enhancers in neurons contributing to AD by comprehensive fine-mapping of DNA methylation at enhancers, genome-wide. We examine 1.2 million CpG and CpH sites in enhancers in prefrontal cortex neurons of individuals with no/mild, moderate, and severe AD pathology (n = 101). We identify 1224 differentially methylated enhancer regions; most of which are hypomethylated at CpH sites in AD neurons. CpH methylation losses occur in normal aging neurons, but are accelerated in AD. Integration of epigenetic and transcriptomic data demonstrates a pro-apoptotic reactivation of the cell cycle in post-mitotic AD neurons. Furthermore, AD neurons have a large cluster of significantly hypomethylated enhancers in the DSCAML1 gene that targets BACE1. Hypomethylation of these enhancers in AD is associated with an upregulation of BACE1 transcripts and an increase in amyloid plaques, neurofibrillary tangles, and cognitive decline.


Subject(s)
Alzheimer Disease/pathology , Cognitive Dysfunction/pathology , Enhancer Elements, Genetic , Neurons/pathology , Prefrontal Cortex/pathology , Aged , Aged, 80 and over , Alzheimer Disease/genetics , Amyloid Precursor Protein Secretases/genetics , Amyloid Precursor Protein Secretases/metabolism , Aspartic Acid Endopeptidases/genetics , Aspartic Acid Endopeptidases/metabolism , Cell Adhesion Molecules/genetics , Cognitive Dysfunction/genetics , Cohort Studies , CpG Islands/genetics , DNA Methylation , Epigenesis, Genetic , Female , Humans , Male , Middle Aged , Prefrontal Cortex/cytology , Up-Regulation
7.
Genome Biol ; 20(1): 2, 2019 01 03.
Article in English | MEDLINE | ID: mdl-30606238

ABSTRACT

BACKGROUND: Maintenance of physiological circadian rhythm plays a crucial role in human health. Numerous studies have shown that disruption of circadian rhythm may increase risk for malignant, psychiatric, metabolic, and other diseases. RESULTS: Extending our recent findings of oscillating cytosine modifications (osc-modCs) in mice, in this study, we show that osc-modCs are also prevalent in human neutrophils. Osc-modCs may play a role in gene regulation, can explain parts of intra- and inter-individual epigenetic variation, and are signatures of aging. Finally, we show that osc-modCs are linked to three complex diseases and provide a new interpretation of cross-sectional epigenome-wide association studies. CONCLUSIONS: Our findings suggest that loss of balance between cytosine methylation and demethylation during the circadian cycle can be a potential mechanism for complex disease. Additional experiments, however, are required to investigate the possible involvement of confounding effects, such as hidden cellular heterogeneity. Circadian rhythmicity, one of the key adaptations of life forms on Earth, may contribute to frailty later in life.


Subject(s)
Aging/metabolism , Circadian Rhythm , Cytosine/metabolism , Epigenesis, Genetic , Neutrophils/metabolism , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/metabolism , Male , Middle Aged , Schizophrenia/metabolism
8.
Clin Cancer Res ; 24(14): 3317-3324, 2018 07 15.
Article in English | MEDLINE | ID: mdl-29615462

ABSTRACT

Purpose: Primary resistance to abiraterone acetate (AA), a key medication for the treatment of metastatic castration-resistant prostate cancer, occurs in 20% to 40% of patients. We aim to identify predictive biomarkers for AA-treatment response and understand the mechanisms related to treatment resistance.Experimental Design: We used the Infinium Human Methylation 450K BeadChip to monitor modification profiles of cell-free circulating DNA (cfDNA) in 108 plasma samples collected from 33 AA-treated patients.Results: Thirty cytosines showed significant modification differences (FDR Q < 0.05) between AA-sensitive and AA-resistant patients during the treatment, of which 21 cytosines were differentially modified prior to treatment. In addition, AA-sensitive patients, but not AA-resistant patients, lost interindividual variation of cfDNA modification shortly after starting AA treatment, but such variation returned to initial levels in the later phases of treatment.Conclusions: Our findings provide a list of potential biomarkers for predicting AA-treatment response, highlight the prognostic value of using cytosine modification variance as biomarkers, and shed new insights into the mechanisms of prostate cancer relapse in AA-sensitive patients. Clin Cancer Res; 24(14); 3317-24. ©2018 AACR.


Subject(s)
Abiraterone Acetate/therapeutic use , Antineoplastic Agents/therapeutic use , Biomarkers, Tumor , Cell-Free Nucleic Acids , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/genetics , Abiraterone Acetate/administration & dosage , Abiraterone Acetate/adverse effects , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Epigenesis, Genetic/drug effects , Humans , Male , Prognosis , Prostatic Neoplasms/blood , Prostatic Neoplasms/mortality , Treatment Outcome
9.
Nat Commun ; 9(1): 644, 2018 02 13.
Article in English | MEDLINE | ID: mdl-29440637

ABSTRACT

Circadian rhythmicity governs a remarkable array of fundamental biological functions and is mediated by cyclical transcriptomic and proteomic activities. Epigenetic factors are also involved in this circadian machinery; however, despite extensive efforts, detection and characterization of circadian cytosine modifications at the nucleotide level have remained elusive. In this study, we report that a large proportion of epigenetically variable cytosines show a circadian pattern in their modification status in mice. Importantly, the cytosines with circadian epigenetic oscillations significantly overlap with the cytosines exhibiting age-related changes in their modification status. Our findings suggest that evolutionary advantageous processes such as circadian rhythmicity can also contribute to an organism's deterioration.


Subject(s)
Aging/genetics , Circadian Rhythm/genetics , Cytosine/metabolism , DNA Methylation/genetics , Epigenesis, Genetic , Animals , Genetic Variation , Male , Mice , Proteomics , Transcriptome
10.
Acta Pharmacol Sin ; 39(5): 866-874, 2018 May.
Article in English | MEDLINE | ID: mdl-29417943

ABSTRACT

Epigenetic gene-regulation abnormalities have been implicated in various neuropsychiatric disorders including schizophrenia and depression, as well as in the regulation of mood and anxiety. In addition, epigenetic mechanisms are involved in the actions of psychiatric drugs. Current anxiolytic drugs have significant shortcomings, and development of new medications is warranted. Two proteins, G9a (also known as EHMT2 or KMT1C) and GLP (G9a-like protein, also known as EHMT1 or KMT1D), which methylate lysine 9 of histone H3 (H3K9), could be promising anxiolytic targets. Postnatal genetic knock-out of G9a reduces anxiety-related behavior, consistent with the reduction of G9a levels by some medications used to treat anxiety (amitriptyline, imipramine and paroxetine). Conversely, there is increased anxiety-like behavior in mice with GLP haplodeficiency. We sought to determine whether two pharmacological inhibitors of G9a/GLP, UNC0642 and A-366, would have similar effects to genetic G9a/GLP insufficiency. We found that G9a/GLP inhibition with either compound reduced anxiety-like behaviors when administered to adult mice, in conjunction with decreased H3K9 methylation in the brain. In contrast, exposure to these compounds from embryonic day 9.5 (E9.5) until birth increased anxiety-like behaviors and decreased social interaction in adulthood, while H3K9 methylation was at normal levels in the brains of the adult mice. These findings reinforce genetic evidence that G9a/GLP has different effects on anxiety-like behavior at different stages of brain development, and suggest that targeting this histone methyltransferase pathway could be useful for developing new anxiolytic drugs. These data also suggest that antidepressant exposure in utero could have negative effects in adulthood, and further investigation of these effects is warranted.


Subject(s)
Anti-Anxiety Agents/therapeutic use , Histone-Lysine N-Methyltransferase/antagonists & inhibitors , Indoles/therapeutic use , Quinazolines/therapeutic use , Spiro Compounds/therapeutic use , Animals , Diazepam/therapeutic use , Dose-Response Relationship, Drug , Epigenesis, Genetic , Female , Histones/genetics , Histones/metabolism , Male , Methylation , Mice, Inbred C57BL , Protein Processing, Post-Translational , Venlafaxine Hydrochloride/therapeutic use
11.
Sci Rep ; 7: 41843, 2017 01 31.
Article in English | MEDLINE | ID: mdl-28139744

ABSTRACT

Transcriptional variation in histologically- and genetically- identical cells is a widespread phenomenon in tissues, yet the processes conferring this heterogeneity are not well understood. To identify contributing factors, we analyzed epigenetic profiles associated with the in vivo transcriptional gradient of the mouse lactase gene (Lct), which occurs in enterocytes along the proximal-to-distal axis of the small intestine. We found that epigenetic signatures at enhancer and promoter elements aligns with transcriptional variation of Lct in enterocytes. Age and phenotype-specific environmental cues (lactose exposure after weaning) induced changes to epigenetic modifications and CTCF binding at select regulatory elements, which corresponded to the alterations in the intestinal Lct mRNA gradient. Thus, epigenetic modifications in combination with CTCF binding at regulatory elements account for the transcriptional gradient in Lct in cells of the same type. Epigenetic divergence within enterocytes may contribute to the functional specialization of intestinal subregions.


Subject(s)
Enterocytes/metabolism , Epigenesis, Genetic , Lactase/genetics , RNA, Messenger/genetics , Animals , CCCTC-Binding Factor/metabolism , Enhancer Elements, Genetic , Enterocytes/drug effects , Gene Expression Regulation, Developmental , Lactase/metabolism , Lactose/pharmacology , Mice , Mice, Inbred C57BL , Promoter Regions, Genetic , RNA, Messenger/metabolism
12.
Nat Struct Mol Biol ; 23(6): 566-73, 2016 06.
Article in English | MEDLINE | ID: mdl-27159559

ABSTRACT

The inability to digest lactose, due to lactase nonpersistence, is a common trait in adult mammals, except in certain human populations that exhibit lactase persistence. It is not known how the lactase gene is dramatically downregulated with age in most individuals but remains active in some individuals. We performed a comprehensive epigenetic study of human and mouse small intestines, by using chromosome-wide DNA-modification profiling and targeted bisulfite sequencing. Epigenetically controlled regulatory elements accounted for the differences in lactase mRNA levels among individuals, intestinal cell types and species. We confirmed the importance of these regulatory elements in modulating lactase mRNA levels by using CRISPR-Cas9-induced deletions. Genetic factors contribute to epigenetic changes occurring with age at the regulatory elements, because lactase-persistence and lactase-nonpersistence DNA haplotypes demonstrated markedly different epigenetic aging. Thus, genetic factors enable a gradual accumulation of epigenetic changes with age, thereby influencing phenotypic outcome.


Subject(s)
Epigenesis, Genetic , Lactase/genetics , Adult , Aged , Aging , Animals , CRISPR-Cas Systems , Chromosomes/genetics , DNA Methylation , Humans , Jejunum/enzymology , Jejunum/metabolism , Lactose Intolerance/enzymology , Lactose Intolerance/genetics , Mice , Mice, Inbred C57BL , Middle Aged , Promoter Regions, Genetic , RNA, Messenger/genetics , Young Adult
13.
Genome Biol ; 17: 76, 2016 Apr 28.
Article in English | MEDLINE | ID: mdl-27122015

ABSTRACT

BACKGROUND: Epigenetic drift progressively increases variation in DNA modification profiles of aging cells, but the finale of such divergence remains elusive. In this study, we explored the dynamics of DNA modification and transcription in the later stages of human life. RESULTS: We find that brain tissues of older individuals (>75 years) become more similar to each other, both epigenetically and transcriptionally, compared with younger individuals. Inter-individual epigenetic assimilation is concurrent with increasing similarity between the cerebral cortex and the cerebellum, which points to potential brain cell dedifferentiation. DNA modification analysis of twins affected with Alzheimer's disease reveals a potential for accelerated epigenetic assimilation in neurodegenerative disease. We also observe loss of boundaries and merging of neighboring DNA modification and transcriptomic domains over time. CONCLUSIONS: Age-dependent epigenetic divergence, paradoxically, changes to convergence in the later stages of life. The newly described phenomena of epigenetic assimilation and tissue dedifferentiation may help us better understand the molecular mechanisms of aging and the origins of diseases for which age is a risk factor.


Subject(s)
Alzheimer Disease/genetics , Epigenesis, Genetic , Frontal Lobe/growth & development , Aged , Aged, 80 and over , DNA Methylation , Female , Frontal Lobe/metabolism , Frontal Lobe/physiology , Humans , Male , Middle Aged , Twins
14.
Am J Hum Genet ; 98(5): 956-962, 2016 May 05.
Article in English | MEDLINE | ID: mdl-27087318

ABSTRACT

Numerous recent studies have suggested that phenotypic effects of DNA sequence variants can be mediated or modulated by their epigenetic marks, such as allele-skewed DNA modification (ASM). Using Affymetrix SNP microarrays, we performed a comprehensive search of ASM effects in human post-mortem brain and sperm samples (total n = 256) from individuals with major psychosis and control individuals. Depending on the phenotypic category of the brain samples, 1.4%-7.5% of interrogated SNPs exhibited ASM effects. Next, we investigated ASM in the context of genetic studies of schizophrenia and detected that brain ASM SNPs were significantly overrepresented among sub-threshold SNPs from a schizophrenia genome-wide association study (GWAS). Brain ASM SNPs showed a much stronger enrichment in a schizophrenia GWAS than in 17 large GWASs of non-psychiatric diseases and traits, arguing that ASM effects are at least partially tissue specific. Studies of germline and control brain ASM SNPs supported a causal association between ASM and schizophrenia. Finally, significantly higher proportions of ASM SNPs than of non-ASM SNPs were detected at loci exhibiting epigenetic signatures of enhancers and promoters, and they were overrepresented within transcription factor binding regions and DNase I hypersensitive sites. All of these findings collectively indicate that ASM SNPs should be prioritized in follow-up GWASs.


Subject(s)
Brain/metabolism , DNA Methylation , Epigenomics , Genome-Wide Association Study/methods , Polymorphism, Single Nucleotide/genetics , Regulatory Sequences, Nucleic Acid/genetics , Schizophrenia/genetics , Alleles , Case-Control Studies , Genetic Predisposition to Disease , Humans , Phenotype , Promoter Regions, Genetic/genetics
15.
Schizophr Bull ; 42(1): 170-7, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26078387

ABSTRACT

New epigenetic technologies may uncover etiopathogenic mechanisms of major psychosis. In this study, we applied padlock probe-based ultra-deep bisulfite sequencing for fine mapping of modified cytosines of the HLA complex group 9 (nonprotein coding) gene in the postmortem brains of individuals affected with schizophrenia or bipolar disorder and unaffected controls. Significant differences between patients and controls were detected in both CpG and CpH modifications. In addition, we identified epigenetic age effects, DNA modification differences between sense and anti-sense strands, and demonstrated how DNA modification data can be used in clustering of patient populations. Our findings revealed new epigenetic complexities but also highlighted the potential of DNA modification approaches in the search of heterogeneous causes of major psychiatric disease.


Subject(s)
Bipolar Disorder/genetics , DNA/metabolism , Prefrontal Cortex/metabolism , RNA, Long Noncoding/genetics , Schizophrenia/genetics , Adult , Aged , Aged, 80 and over , Bipolar Disorder/metabolism , Brain/metabolism , Cadaver , Case-Control Studies , DNA Methylation , Epigenesis, Genetic , Female , Humans , Male , Middle Aged , Psychotic Disorders/genetics , Psychotic Disorders/metabolism , RNA, Long Noncoding/metabolism , Schizophrenia/metabolism , Sequence Analysis, DNA
16.
Biol Psychiatry ; 77(3): 246-255, 2015 Feb 01.
Article in English | MEDLINE | ID: mdl-25108803

ABSTRACT

BACKGROUND: Major depressive disorder (MDD) exhibits numerous clinical and molecular features that are consistent with putative epigenetic misregulation. Despite growing interest in epigenetic studies of psychiatric diseases, the methodologies guiding such studies have not been well defined. METHODS: We performed DNA modification analysis in white blood cells from monozygotic twins discordant for MDD, in brain prefrontal cortex, and germline (sperm) samples from affected individuals and control subjects (total N = 304) using 8.1K CpG island microarrays and fine mapping. In addition to the traditional locus-by-locus comparisons, we explored the potential of new analytical approaches in epigenomic studies. RESULTS: In the microarray experiment, we detected a number of nominally significant DNA modification differences in MDD and validated selected targets using bisulfite pyrosequencing. Some MDD epigenetic changes, however, overlapped across brain, blood, and sperm more often than expected by chance. We also demonstrated that stratification for disease severity and age may increase the statistical power of epimutation detection. Finally, a series of new analytical approaches, such as DNA modification networks and machine-learning algorithms using binary and quantitative depression phenotypes, provided additional insights on the epigenetic contributions to MDD. CONCLUSIONS: Mapping epigenetic differences in MDD (and other psychiatric diseases) is a complex task. However, combining traditional and innovative analytical strategies may lead to identification of disease-specific etiopathogenic epimutations.


Subject(s)
Depressive Disorder, Major/genetics , Epigenesis, Genetic , Adolescent , Adult , Aged , CpG Islands , Female , Humans , Leukocytes , Male , Microarray Analysis , Middle Aged , Prefrontal Cortex , Spermatozoa , Twins, Monozygotic , Young Adult
17.
Hum Mol Genet ; 21(16): 3619-31, 2012 Aug 15.
Article in English | MEDLINE | ID: mdl-22619380

ABSTRACT

Epigenetic differences are a common feature of many diseases, including cancer, and disease-associated changes have even been detected in bodily fluids. DNA modification studies in circulating DNA (cirDNA) may lead to the development of specific non-invasive biomarkers. To test this hypothesis, we investigated cirDNA modifications in prostate cancer patients with locally confined disease (n = 19), in patients with benign prostate hyperplasias (n = 20) and in men without any known prostate disease (n = 20). This initial discovery screen identified 39 disease-associated changes in cirDNA modification, and seven of these were validated using the sodium bisulfite-based mapping of modified cytosines in both the discovery cohort and an independent 38-patient validation cohort. In particular, we showed that the DNA modification of regions adjacent to the gene encoding ring finger protein 219 distinguished prostate cancer from benign hyperplasias with good sensitivity (61%) and specificity (71%). We also showed that repetitive sequences detected in this study were meaningful, as they indicated a highly statistically significant loss of DNA at the pericentromeric region of chromosome 10 in prostate cancer patients (p = 1.8 × 10(-6)). Based on these strong univariate results, we applied machine-learning techniques to develop a multi-locus biomarker that correctly distinguished prostate cancer samples from unaffected controls with 72% accuracy. Lastly, we used systems biology techniques to integrate our data with publicly available DNA modification and transcriptomic data from primary prostate tumors, thereby prioritizing genes for further studies. These data suggest that cirDNA epigenomics are promising source for non-invasive biomarkers.


Subject(s)
Biomarkers, Tumor/genetics , DNA, Circular/blood , Epigenesis, Genetic , Prostatic Neoplasms/genetics , Aged , Biomarkers, Tumor/blood , Case-Control Studies , Centromere , Chromosomes, Human, Pair 10 , Cytosine/chemistry , DNA Methylation , Gene Expression Regulation, Neoplastic , Humans , Male , Microarray Analysis/methods , Middle Aged , Prostatic Hyperplasia/genetics , Repetitive Sequences, Nucleic Acid , Sensitivity and Specificity
18.
Prog Neuropsychopharmacol Biol Psychiatry ; 37(1): 62-75, 2012 Apr 27.
Article in English | MEDLINE | ID: mdl-22203087

ABSTRACT

OBJECTIVES: This study aimed to: 1) replicate previously reported associations between dopamine D4 receptor gene (DRD4) polymorphisms and antipsychotic (AP) response in a clozapine (CLZ) response sample; and 2) explore possible associations of polymorphisms across dopamine D5 receptor gene (DRD5) as well as other DRD4 regions. METHODS: DRD4 exon III 48-bp, intron I (G)(n), and 120-bp repeat polymorphisms, and three DRD4 single nucleotide polymorphisms (SNPs); and DRD5 (CA/CT/GT)(n) microsatellite and four DRD5 SNPs were assessed using standard genotyping and statistical procedures. RESULTS: We report evidence, which does not survive correction for multiple testing, supporting previous DRD4 findings. Findings of interest include the 120-bp 1-copy allele, intron I (G)(n) 142-bp/140-bp genotype, and exon III 4R allele with CLZ response. All DRD5 tests were negative. CONCLUSIONS: Overall, these results suggest a possible minor contribution of DRD4 variants, but not DRD5 variants, towards the AP/CLZ response phenotype.


Subject(s)
Clozapine/therapeutic use , Genetic Variation/genetics , Receptors, Dopamine D4/genetics , Receptors, Dopamine D5/genetics , Schizophrenia/drug therapy , Schizophrenia/genetics , Antipsychotic Agents/therapeutic use , Black People/genetics , Female , Humans , Male , Polymorphism, Single Nucleotide/genetics , Prospective Studies , Schizophrenia/ethnology , Treatment Outcome , White People/genetics
19.
Behav Brain Res ; 217(2): 379-85, 2011 Mar 01.
Article in English | MEDLINE | ID: mdl-21070817

ABSTRACT

The precise mechanisms underlying the memory-blocking properties of ethanol are unknown, in part because ethanol targets a wide array of neurotransmitter receptors and transporters. The aim of this study was to determine whether the memory loss caused by ethanol is mediated, in part, by α5 subunit-containing γ-aminobutyric acid subtype A receptors. These receptors have been implicated in learning and memory processes and are targets for a variety of neurodepressive drugs. Also, since these receptors generate a tonic inhibitory current in hippocampal pyramidal neurons, we examined whether concentrations of ethanol that block memory in vivo increased the tonic current using whole-cell patch-clamp recordings in hippocampal neurons. Null mutant mice lacking the α5 subunit (Gabra5-/-) and wild-type mice were equally impaired in contextual fear conditioning by moderate (1mg/kg) and high (1.5mg/kg) doses of ethanol. The higher dose of ethanol also reduced auditory delay fear conditioning to the same extent in the two genotypes. Interestingly, wild-type mice were more sensitive than Gabra5-/- mice to the sedative effects of low (0.5mg/kg) and moderate (1mg/kg) doses of ethanol in the open-field task. Concentrations of ethanol that impaired memory performance in vivo did not increase the amplitude of the tonic current. Together, the results suggest that the α5-subunit containing γ-aminobutyric acid subtype A receptors are not direct targets for positive modulation by ethanol nor do they contribute to ethanol-induced memory loss. In contrast, these receptors may contribute to the sedative properties of ethanol.


Subject(s)
Central Nervous System Depressants/pharmacology , Conditioning, Psychological/drug effects , Ethanol/pharmacology , Fear/drug effects , Memory Disorders/chemically induced , Receptors, GABA-A/metabolism , Acoustic Stimulation/adverse effects , Animals , Behavior, Animal , Cells, Cultured , Conditioning, Psychological/physiology , Dose-Response Relationship, Drug , Electric Stimulation/methods , Exploratory Behavior/drug effects , Freezing Reaction, Cataleptic/drug effects , Freezing Reaction, Cataleptic/physiology , Hippocampus/cytology , Locomotion/drug effects , Locomotion/genetics , Membrane Potentials/drug effects , Membrane Potentials/genetics , Memory Disorders/genetics , Mice , Mice, Knockout , Patch-Clamp Techniques , Pyramidal Cells/drug effects , Pyramidal Cells/physiology , Receptors, GABA-A/deficiency , Time Factors
20.
Anesthesiology ; 111(5): 1025-35, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19809285

ABSTRACT

BACKGROUND: The memory-blocking properties of general anesthetics have recently received considerable attention because of concerns related to intraoperative awareness and postoperative cognitive dysfunction. The goal of this study was to identify the mechanisms by which gamma-aminobutyric acid subtype A receptors that contain the alpha5 subunit (alpha5GABAARs) induce memory-blockade by etomidate and a pharmacologic strategy to reverse this impairment. METHODS: The effects of etomidate and the alpha5GABAAR-preferring inverse agonist L-655,708 on the plasticity of glutamatergic excitatory transmission in hippocampal slices and behavioral memory for spatial navigational and fear-associated memory tasks were studied in wild-type and null mutant mice for the gene that encodes the alpha5 subunit (Gabra5-/- mice). Long-term potentiation of field excitatory postsynaptic potentials was induced in CA1 pyramidal neurons following high-frequency stimulation of Schaffer collaterals. Memory performance was studied in contextual, cued, and trace fear conditioning assays and the Morris water maze. RESULTS: Robust synaptic plasticity induced by high-frequency stimulation and memory performance for contextual fear and spatial navigational memory were not influenced by a decrease in the function of alpha5GABAARs. Nevertheless, etomidate, via an increase in alpha5GABAAR activity, completely blocked long-term potentiation and impaired memory performance, and these effects were reversed by pretreatment with L-655,708. CONCLUSIONS: The results provide the first proof of concept that memory blockade by a general anesthetic can be reversed by inhibiting the function of alpha5GABAARs. The findings suggest a mechanism and model for awareness during anesthesia.


Subject(s)
Anesthetics, Intravenous/pharmacology , Etomidate/pharmacology , Memory/drug effects , Neuronal Plasticity/drug effects , Receptors, GABA-A/drug effects , Synapses/drug effects , Animals , Anxiety/etiology , Fear/psychology , Hippocampus/drug effects , Hippocampus/physiology , Imidazoles/pharmacology , Long-Term Potentiation/drug effects , Male , Mice , Mice, Inbred C57BL , Receptors, GABA-A/physiology , Synapses/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...